Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005617 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005617 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center.
The verdict
NCT00005617, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV, or relapsed malignant melanoma.
Interventions
- PROCEDURE leukapheresis
- BIOLOGICAL dendritic cell-MART-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005617
The ClinicalTrials.gov registry entry for NCT00005617 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which leukapheresis is the first listed.
NCT00005617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005617 about?
NCT00005617 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV, or relapsed malignant melanoma.
What is the current status of trial NCT00005617?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-07.
What interventions are being tested in trial NCT00005617?
The interventions under investigation include: leukapheresis (PROCEDURE), dendritic cell-MART-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005617?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.